Pregabalin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Diabetic Peripheral Neuropathic Pain, Epilepsy (label: adjunctive therapy for partial-onset seizures), Fibromyalgia, Diabetic Peripheral Neuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Management of postherpetic neuralgiaOutside this platform's coverage
  • Management of neuropathic pain associated with spinal cord injury
Product first approved 2004FDA label
JP
  • Treatment of postherpetic neuralgia
Product first approved 2010Outside this platform's coveragePMDA
EU
  • Neuropathic pain Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised anxiety disorder Lyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (117)
Diabetic Peripheral Neuropathic Pain
NCT07712913 · Brainfarma Industria Química e Farmacêutica S/A
2026-06-18 – 2027-06-01 · Diabetic Neuropathy, Neuropathic Pain, Neuralgia, Postherpetic
What this study did
NCT06383702 · CSPC Ouyi Pharmaceutical Co., Ltd.
2024-05-15 – 2025-04-15 · Painful Diabetic Neuropathy
What this study did
NCT01332149 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-07 – 2014-06 · Diabetic Neuropathy, Painful
What this study did
NCT02927951 · Eastern Virginia Medical School
2011-01 – 2013-12 · Diabetic Peripheral Neuropathy, Nerve Pain
What this study did
NCT01455415 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-12 – 2013-12 · Painful Diabetic Peripheral Neuropathy
What this study did
NCT01474772 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-10 – 2013-07 · Diabetic Peripheral Neuropathy
What this study did
NCT01057693 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-03-31 – 2012-01-30 · Diabetic Neuropathy, Painful
What this study did
NCT01089556 · Eli Lilly and Company
2010-03 – 2011-11 · Diabetic Neuropathy, Painful
What this study did
NCT00553280 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-02 – 2010-01 · Diabetic Neuropathy, Painful
What this study did
NCT00553475 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-10 – 2009-03 · Diabetic Neuropathy, Painful
What this study did
NCT00141219 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-12 – 2007-12 · Diabetic Neuropathies, Neuralgia
What this study did
NCT00143156 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-03 – 2007-05 · Diabetic Neuropathies
What this study did
Epilepsy
NCT00448916 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2013-10 · Epilepsies, Partial
What this study did
NCT01262677 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-02-17 – 2012-08-01 · Partial Seizures, Epilepsies, Partial
What this study did
NCT00537238 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-10 – 2012-05 · Partial Seizures
What this study did
NCT00596466 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-04 – 2011-12 · Epilepsy
What this study did
NCT00372528 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-03 – 2011-10 · Epilepsy
What this study did
NCT00524030 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-09 – 2011-06 · Epilepsies, Partial
What this study did
NCT00280059 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-08 – 2010-04 · Epilepsy, Partial
What this study did
NCT00143130 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-04 – 2007-09 · Seizures
What this study did
NCT00141258 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-10 – 2006-08 · Partial Seizures
What this study did
NCT00143143 · Pfizer
2001-09 – 2006-02 · Epilepsies, Partial, Epilepsy, Complex Partial
What this study did
NCT00150293 · Pfizer
2002-03 – 2005-11 · Seizure Disorder, Partial
What this study did
NCT00141336 · Pfizer
1999-11 – 2005-07 · Seizure Disorder, Partial
What this study did
NCT00643136 · Pfizer
2002-11 – 2004-06 · Sleep Deprivation, Epilepsies, Partial
What this study did
Fibromyalgia
NCT02868814 · Jiangsu HengRui Medicine Co., Ltd.
2016-05 – 2019-05 · Fibromyalgia
What this study did
NCT02187471 · Daiichi Sankyo
2015-01-16 – 2017-01-12 · Pain Associated With Fibromyalgia
What this study did
NCT01387607 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2012-02-06 – 2016-10-31 · Fibromyalgia
What this study did
NCT01432236 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-10 – 2013-07 · Fibromyalgia
What this study did
NCT01271933 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-03 – 2012-07 · Fibromyalgia
What this study did
NCT00830167 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-03 – 2011-05 · Fibromyalgia
What this study did
NCT00830128 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-07 – 2011-02 · Fibromyalgia
What this study did
NCT00883740 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-06 – 2010-06 · Fibromyalgia, Sleep Disorders
What this study did
NCT00797797 · Forest Laboratories
2008-11 – 2010-01 · Fibromyalgia
What this study did
NCT00346034 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-12 – 2008-02 · Fibromyalgia
What this study did
NCT00282997 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-02 – 2006-10 · Fibromyalgia
What this study did
NCT00230776 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-10 – 2006-07 · Fibromyalgia
What this study did
NCT00151489 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-04 – 2006-06 · Fibromyalgia
What this study did
NCT00151528 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-01 – 2006-06 · Fibromyalgia
What this study did
Other / comorbidity
NCT06516094 · Laboratorios Silanes S.A. de C.V.
2024-04-11 – 2025-01-07 · Chronic Low-back Pain
What this study did
Phase 2/3 (16)
Fibromyalgia
NCT02639533 · Hospital de Clinicas de Porto Alegre
2014-12 – 2017-01 · Fibromyalgia
What this study did
Other / comorbidity
NCT04122196 · University of Missouri-Columbia
2020-06-01 – 2024-07-01 · Kidney Stone, Pain, Postoperative, Addiction, Opioid Use
What this study did
NCT06117917 · Beijing Tiantan Hospital
2023-11-10 – 2024-06-30 · Esketamine, Pregabaline, Chronic Post Operative Pain
What this study did
NCT05160493 · Beijing Tiantan Hospital
2021-12-20 – 2024-06-20 · Chronic Postsurgical Pain
What this study did
NCT05389813 · An-Najah National University
2021-08-15 – 2024-05-01 · Anesthesia
What this study did
NCT05509946 · Universitas Indonesia
2022-10-01 – 2023-04-30 · Arthroplasty Complications, Analgetic, Celecoxib, Pregabalin
What this study did
NCT05096468 · Beijing Tiantan Hospital
2021-12-01 – 2022-10-15 · Esketamine, Pregabalin, Acute Postoperative Pain, Neurosurgical Procedures, Perioperative Complication, Spinal Cord Neoplasms
What this study did
NCT03229668 · Saint Savvas Anticancer Hospital
2017-07-28 – 2020-02-20 · Pregabalin on Catheter Related Bladder Discomfort
What this study did
NCT04342065 · South Egypt Cancer Institute
2019-01-01 – 2020-02-01 · Post-Operative Pain
What this study did
NCT03232021 · Saint Savvas Anticancer Hospital
2017-08-16 – 2019-04-30 · Pregabalin on Catheter Related Bladder Discomfort
What this study did
NCT02701764 · University of Miami
2016-07-26 – 2018-12-01 · Dry Eye
What this study did
NCT01701921 · Larissa University Hospital
2011-07 – 2016-06 · Postoperative Pain
What this study did
NCT02724293 · Assiut University
2014-09 – 2015-11 · Postoperative Pain Following Radical Cystectomy
What this study did
NCT01021696 · University of Bergen
2009-11 – 2010-10 · Dementia, Pain, Agitation
What this study did
NCT00755573 · Aalborg University Hospital
2008-10 – 2010-05 · Chronic Pancreatitis
What this study did
NCT00370656 · University of Surrey
2007-02 – 2009-05 · Diabetes Mellitus, Peripheral Neuropathies
What this study did
Phase 2 (49)
Diabetic Peripheral Neuropathic Pain
NCT06614322 · University of Rochester
2026-02-02 – 2028-06-01 · Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
What this study did
NCT06490484 · Haisco Pharmaceutical Group Co., Ltd.
2024-04-19 – 2024-07-14 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT01314222 · Bristol-Myers Squibb
2011-03 – 2012-07 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT00837941 · Merck Sharp & Dohme LLC
2009-04 – 2009-09 · Painful Diabetic Neuropathy
What this study did
NCT00643760 · XenoPort, Inc.
2008-03 – 2009-02 · Neuropathy, Diabetic
What this study did
Epilepsy
NCT00629889 · Dr Andrea Rossetti
2008-02 – 2013-05 · Brain and Central Nervous System Tumors, Seizure
What this study did
NCT00141414 · Pfizer
1997-11 – 2005-10 · Epilepsy, Partial
What this study did
Fibromyalgia
NCT01904097 · Hospital de Clinicas de Porto Alegre
2013-03 – 2014-12 · Fibromyalgia, Chronic Pain
What this study did
Other / comorbidity
NCT06150898 · Jules Bordet Institute
2025-05-12 – 2027-10 · Early-stage Breast Cancer, Estrogen-receptor-positive Breast Cancer
What this study did
NCT07913074 · Tavo Biotherapeutics
2026-10-23 – 2027-09-30 · Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
What this study did
NCT07275762 · Neurodawn Pharmaceutical Co., Ltd.
2026-02-02 – 2026-11-30 · Postherpetic Neuralgia, Y-4, Pregabalin
What this study did
NCT05995535 · University of Pennsylvania
2024-09-01 – 2026-08-31 · Opiate Withdrawal Syndrome, Opioid Use
What this study did
NCT05967052 · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
2023-10-24 – 2025-09-11 · Chronic Fatigue Syndrome, COVID-19, Long Haul
What this study did
NCT06417580 · Jesuína Lamartine Nogueira Araújo
2024-05-28 – 2024-09-28 · Dentin Sensitivity
What this study did
NCT04173390 · InCor Heart Institute
2021-03-01 – 2023-11-01 · Postoperative Pain
What this study did
NCT04218240 · University of Pennsylvania
2020-12-17 – 2023-08-31 · Opioid Withdrawal
What this study did
NCT04322305 · New York State Psychiatric Institute
2021-01-11 – 2023-07-31 · Alcohol Use Disorder
What this study did
NCT04660773 · Alexandria University
2021-08-01 – 2022-03-01 · Refractory Uremic Pruritis
What this study did
NCT05083793 · Assiut University
2020-04-01 – 2022-01-01 · Postoperative Pain
What this study did
NCT04495283 · Nevakar, Inc.
2020-07-28 – 2020-11-12 · Postoperative Pain
What this study did
NCT03256253 · New York State Psychiatric Institute
2018-02-15 – 2020-05-31 · Alcohol Use Disorder
What this study did
NCT04181346 · Faculdade de Medicina do ABC
2019-09-01 – 2020-02-28 · Nausea
What this study did
NCT03735368 · Abd-Elazeem Abd-Elhameed Elbakry
2018-12-10 – 2019-11-29 · Conscious Sedation
What this study did
NCT01846182 · VA Office of Research and Development
2015-06-24 – 2019-08-01 · Gulf War Illness
What this study did
NCT02924675 · University Hospital, Lille
2015-06-05 – 2018-12-12 · Earache
What this study did
NCT03669081 · University of Utah
2016-09-20 – 2018-09-30 · Pain, Postoperative
What this study did
NCT03652818 · Nevakar, Inc.
2018-06-15 – 2018-09-20 · Dental Pain
What this study did
NCT02607254 · Johns Hopkins University
2015-09 – 2018-07 · Idiopathic Small Fiber Neuropathy
What this study did
NCT03407430 · UNC Lineberger Comprehensive Cancer Center
2016-01-27 – 2017-07-20 · Breast Cancer, Lymphoma, Pain
What this study did
NCT01869569 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2013-02 – 2017-01 · Neuropathic Pain
What this study did
NCT01637077 · Academic and Community Cancer Research United
2012-01 – 2016-04 · Pain, Peripheral Neuropathy
What this study did
NCT01821430 · Georgetown University
2013-03 – 2016-02 · Chronic Pain
What this study did
NCT00977197 · Mayo Clinic
2010-03 – 2015-06 · Irritable Bowel Syndrome
What this study did
NCT02024568 · Assaf-Harofeh Medical Center
2013-12 – 2015-05 · Taxane, Drug-related Side Effects and Adverse Reactions, Pain, Breast Cancer
What this study did
NCT01675986 · Poitiers University Hospital
est. completion 2014-11 · Feeling Anxious
What this study did
NCT00929344 · The Scripps Research Institute
2009-07 – 2014-10 · Alcohol Dependence
What this study did
NCT00853229 · The Cleveland Clinic
2009-02 – 2013-04 · Vulvodynia, Vulvar Vestibulitis
What this study did
NCT01571804 · Mansoura University
2011-12 – 2012-03 · Elective Laparoscopic Cholecystectomy, Sevoflurane Anesthesia
What this study did
NCT01529190 · Federal University of São Paulo
2011-03 – 2011-12 · Pain
What this study did
NCT00637975 · Associazione Progetto Oncologia UMAN.A
2007-09 – 2010-12 · Cancer, Pain
What this study did
NCT00852436 · University of Toronto
2009-02 – 2010-10 · Neuropathic Pain, Orofacial Pain
What this study did
NCT00558753 · Rush University Medical Center
2006-04 – 2010-06 · CRPS
What this study did
NCT00676403 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-04 – 2009-01 · Restless Legs Syndrome
What this study did
NCT00599638 · Pfizer
2008-04-09 – 2008-12-23 · Postherpetic Neuralgia
What this study did
NCT00334685 · Pfizer
2006-08-22 – 2007-10-11 · Pain
What this study did
NCT00352651 · University of California, San Francisco
2006-06 – 2006-12 · Herpes Zoster, Postherpetic Neuralgia
What this study did
NCT00746681 · Pfizer
2005-12 – 2006-11 · Overactive Bladder
What this study did
NCT00245609 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-01 – 2006-10 · Dental Anxiety
What this study did
Phase 1/2 (7)
Epilepsy
NCT00437281 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-04 – 2012-11 · Epilepsies, Partial
What this study did
Fibromyalgia
NCT02451475 · Mansoura University
2013-02 – 2014-10 · Fibromyalgia
What this study did
Other / comorbidity
NCT05442931 · Minia University
2022-05-01 – 2022-10-30 · Functional Endoscopic Sinus Surgery
What this study did
NCT02482818 · Ottawa Hospital Research Institute
2015-09 – 2021-12-31 · Cough
What this study did
NCT04622202 · Zagazig University
2020-11-15 – 2021-03-01 · Anxiety State, Sedation
What this study did
NCT05547659 · October 6 University
2019-01-01 – 2020-12-01 · Compare Unimodal and Multimodal Analgesics
What this study did
NCT01333956 · Hospital for Special Surgery, New York
2011-05 – 2013-06 · Primary Total Knee Arthroplasty
What this study did
Phase 1 (51)
Diabetic Peripheral Neuropathic Pain
NCT05292066 · Aga Khan University
2022-10 – 2022-12 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT00570310 · Merck Sharp & Dohme LLC
2007-12 – 2008-09 · Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
What this study did
Fibromyalgia
NCT00760474 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-01 – 2011-03 · Fibromyalgia
What this study did
Other / comorbidity
NCT07752134 · Beijing Tiantan Hospital
2026-12-31 – 2027-12-31 · Bladder Pain Syndrome, Pregabalin, Educational Behavioral Intervention, Urinary Urgency
What this study did
NCT07400471 · Chattogram International Dental College
2026-02-06 – 2027-04-30 · Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain Sensitivity
What this study did
NCT05150795 · Ain Shams University
2022-01-01 – 2026-12 · Post Operative Pain, Acute
What this study did
NCT07618715 · Neurodawn Pharmaceutical Co., Ltd.
2026-06-30 – 2026-10-31 · Healthy Male and Female Subjects
What this study did
NCT04862845 · Cairo University
2021-07-30 – 2026-01-01 · Postoperative Pain
What this study did
NCT06935721 · Beijing Tiantan Hospital
2025-03-28 – 2025-06 · Healthy Male and Female Subjects
What this study did
NCT06512155 · Mengchang Yang
2024-07-02 – 2024-12-26 · Sleep Disorder
What this study did
NCT05829148 · Egymedicalpedia
2023-05-01 – 2024-11-20 · Endoscopic Sinus Surgery
What this study did
NCT06600607 · Latigo Biotherapeutics
2024-10-07 – 2024-10-27 · Pain Detection, Pain Threshold
What this study did
NCT06077786 · H. Lundbeck A/S
2023-10-13 – 2024-05-17 · Healthy Participants
What this study did
NCT04265456 · Nevakar, Inc.
2020-01-14 – 2020-07-22 · Postoperative Pain
What this study did
NCT05370716 · CrystalGenomics, Inc.
2019-11-11 – 2020-05-19 · Healthy
What this study did
NCT01511640 · Joshua A. Lile, Ph.D.
2017-02-01 – 2020-03-15 · Cannabis-use Disorders
What this study did
NCT03618589 · Seoul National University Hospital
2016-11-26 – 2019-12-31 · Pain, Neuropathic
What this study did
NCT03473093 · Assiut University
2018-03 – 2019-04 · Fracture; Rib, Multiple
What this study did
NCT05389150 · Laboratorios Silanes S.A. de C.V.
2019-01-17 – 2019-03-27 · Healthy
What this study did
NCT02952937 · GL Pharm Tech Corporation
2016-11 – 2017-04 · Healthy
What this study did
NCT02955472 · GL Pharm Tech Corporation
2016-11 – 2017-04 · Healthy
What this study did
NCT02783183 · Yuhan Corporation
2016-06 – 2016-11 · Peripheral Nueropathy Pain
What this study did
NCT02783638 · Yuhan Corporation
2016-01 – 2016-09 · Peripheral Neuropathy Pain
What this study did
NCT02725112 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2016-02-12 – 2016-06-17 · Healthy
What this study did
NCT01719705 · Mansoura University
2012-11 – 2015-06 · Uncomplicated Singleton Pregnancies
What this study did
NCT02349607 · Pfizer
2015-01 – 2015-03 · Healthy
What this study did
NCT01638273 · GL Pharm Tech Corporation
2014-02 – 2014-11 · Healthy
What this study did
NCT01808300 · Unimed Pharmaceuticals
2013-02 – 2013-08 · Healthy
What this study did
NCT01342198 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-06 – 2011-07 · Healthy
What this study did
NCT01202435 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-10 – 2010-11 · Healthy
What this study did
NCT01202422 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-10 – 2010-11 · Healthy
What this study did
NCT01122004 · Shahid Beheshti University of Medical Sciences
— · Refractive Errors
What this study did
NCT00644137 · Yale University
2007-08 – 2010-02 · Nicotine Dependence
What this study did
NCT01009541 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-11 – 2009-12 · Healthy
What this study did
NCT00583869 · University of Alabama at Birmingham
2007-05 – 2009-08 · Post-operative Pain
What this study did
NCT00654940 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-05 – 2009-02 · Nerve Pain
What this study did
NCT00646451 · Baylor College of Medicine
2006-06 – 2008-12 · Essential Tremor
What this study did
Phase 4 (125)
Diabetic Peripheral Neuropathic Pain
NCT07313111 · Hawler Medical University
2024-07-01 – 2025-09-01 · Diabetic Peripheral Neuropathy (DPN)
What this study did
NCT04846673 · Yuhan Corporation
2021-05-14 – 2022-11-30 · Diabetic Peripheral Neuropathy
What this study did
NCT04246619 · KRKA
2019-11-12 – 2021-12-21 · Painful Diabetic Peripheral Neuropathy
What this study did
NCT03712475 · Yung Shin Pharm. Ind. Co., Ltd.
2018-01-19 – 2018-12-03 · Diabetic Peripheral Neuropathy, Fibromyalgia, Partial Seizure Disorder
What this study did
NCT01770964 · Analgesic Solutions
2012-12 – 2013-07 · Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
What this study did
NCT01116531 · Turku University Hospital
2010-04 – 2012-12 · Diabetic Polyneuropathy, Postherpetic Neuralgia
What this study did
NCT00407511 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-01 – 2008-07 · Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
What this study did
NCT00573261 · Duke University
2006-03 – 2008-05 · Diabetic Neuropathy
What this study did
NCT00156078 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-01 – 2007-05 · Diabetic Neuropathy, Painful
What this study did
NCT00159731 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-01 – 2006-05 · Diabetic Peripheral Neuropathy
What this study did
NCT00629681 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-11 – 2006-02 · Painful Diabetic Neuropathy and Post Herpetic Neuralgia
What this study did
NCT00159679 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-09 – 2005-10 · Diabetic Neuropathy, Painful
What this study did
Epilepsy
NCT00351611 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-07-26 – 2020-02-04 · Epilepsies, Partial
What this study did
NCT01128712 · Northeast Regional Epilepsy Group
2010-04 – 2014-07 · Epilepsy, Complex Partial
What this study did
NCT00537940 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-02 – 2013-07 · Epilepsy, Partial Seizure Disorder, Epilepsies, Partial, Complex Partial Seizure Disorder
What this study did
NCT01309074 · Rush University Medical Center
2009-11 – 2012-12 · Epilepsy, Anxiety
What this study did
NCT00407797 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-03 – 2009-08 · Partial Seizures
What this study did
NCT00288639 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-12 – 2007-12 · Epilepsy
What this study did
NCT00141427 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-11 – 2006-05 · Seizures
What this study did
Fibromyalgia
NCT02747940 · Taipei Veterans General Hospital, Taiwan
2015-12 – 2019-12 · Chronic Pain, Chronic Migraine, Fibromyalgia
What this study did
NCT01020526 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-09 – 2015-06 · Fibromyalgia
What this study did
NCT01020474 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-05 – 2014-12 · Fibromyalgia
What this study did
NCT01397006 · Newton-Wellesley Hospital
2011-09 – 2014-03 · Fibromyalgia
What this study did
NCT01226667 · Osteoporosis Medical Center, Beverly Hills, CA
2010-07 – 2012-07 · Fibromyalgia
What this study did
NCT00791739 · Universidad de Granada
2008-04 – 2009-10 · Fibromyalgia
What this study did
Other / comorbidity
NCT07288528 · McMaster University
2026-09-30 – 2029-10-01 · Cough, Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity Syndrome, Chronic Cough
What this study did
NCT05488847 · Henry Ford Health System
2022-06-25 – 2026-09-01 · Shoulder Arthropathy, Shoulder Pain
What this study did
NCT06790537 · Post Graduate Institute of Medical Education and Research, Chandigarh
2025-04-17 – 2026-06-30 · Diabetic Pruritus, Efficacy of Pregabalin in Controlling Diabetic Pruritus Severity
What this study did
NCT05640453 · Tanta University
2022-12-15 – 2026-05-15 · Pregabalin, Delirium Treatment, Coronary Artery Bypass Grafting, Dexmedetomidine
What this study did
NCT07567924 · Subas Ali
2024-02-06 – 2026-05-15 · Post Mastectomy Pain Syndrome
What this study did
NCT06367998 · The Catholic University of Korea
2024-09-01 – 2026-05-01 · Rotator Cuff Tears, Central Sensitisation, Neuropathic Pain
What this study did
NCT05478382 · Ajou University School of Medicine
2022-10 – 2025-12-31 · Postoperative Pain, Pregabalin, Spine Surgery, Adverse Reaction to Pregabalin
What this study did
NCT07866443 · National and Kapodistrian University of Athens
2025-03-01 – 2025-12-20 · Myofascial Pain Syndrome - Neck
What this study did
NCT05804591 · Medical University of Warsaw
2023-04-24 – 2025-08-01 · Obesity, Postoperative Pain, Postoperative Nausea and Vomiting, Opioid Use
What this study did
NCT06187922 · Bahrain Defence Force Hospital
2023-09-01 – 2025-07-30 · Postoperative Pain
What this study did
NCT05640479 · Tanta University
2022-12-15 – 2025-01-02 · Pregabalin, Dexmedetomidine, Delirium
What this study did
NCT06401499 · Muhammad Ilyas
2024-06-01 – 2024-12-31 · Back Pain Lower Back Chronic
What this study did
NCT04705480 · CAMC Health System
2021-04-12 – 2024-12-13 · Analgesics, Gabapentin, Injuries, Narcotics, Pain, Trauma
What this study did
NCT05447364 · Thammasat University
2021-07-01 – 2024-03-01 · Knee Osteoarthritis
What this study did
NCT05460871 · University of Iowa
2023-02-21 – 2024-01-25 · Osteo Arthritis Knee, Central Nervous System Sensitization
What this study did
NCT05974501 · University of Miami
2023-09-29 – 2024-01-22 · Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain
What this study did
NCT05598905 · Leiden University Medical Center
2022-10-10 – 2024-01-12 · Opioid-induced Respiratory Depression
What this study did
NCT04015908 · University of Utah
2019-08-01 – 2023-01-31 · Opioid Use
What this study did
NCT05432843 · Universitaire Ziekenhuizen KU Leuven
2010-03-12 – 2023-01 · Globus Sensation
What this study did
NCT05221151 · Menoufia University
2022-01-30 – 2022-10-02 · Anxiety
What this study did
NCT05324761 · Al-Kindy College of Medicine
2022-04-25 – 2022-06-30 · Failed Back Surgery Syndrome
What this study did
NCT05053126 · Viatris Specialty LLC
2021-07-27 – 2022-04-01 · Abuse Potential
What this study did
NCT04766996 · Emory University
2021-05-17 – 2021-12-27 · Anesthesia, Opioid Use
What this study did
NCT04782310 · Cairo University
2021-03-10 – 2021-09-15 · Postoperative Pain
What this study did
Early phase / not applicable (83)
Diabetic Peripheral Neuropathic Pain
NCT06336486 · Busra Gunes
2018-12-04 – 2020-02-01 · Diabetic Neuropathic Pain
What this study did
NCT01180608 · Universitair Ziekenhuis Brussel
2010-09 – 2012-09 · Diabetic Neuropathies, Pain
What this study did
Fibromyalgia
NCT07171320 · Beijing Tiantan Hospital
2025-09-15 – 2027-08-31 · Fibromyalgia, Pregabalin, Pain
What this study did
NCT07208357 · Beijing Tiantan Hospital
2025-10-20 – 2027-08-31 · Fibromyalgia, Pregabalin, Duloxetine, Pain
What this study did
NCT07230197 · Beijing Tiantan Hospital
2025-09-30 – 2027-08-31 · Fibromyalgia, Pregabalin, Dexmedetomidine
What this study did
NCT07186751 · Beijing Tiantan Hospital
2025-09-20 – 2027-08-31 · Fibromyalgia, Pregabalin, Venlafaxine, Pain
What this study did
NCT07230171 · Beijing Tiantan Hospital
2025-09-15 – 2026-08-30 · Fibromyalgia, Pregabalin, Esketamine
What this study did
NCT07382921 · Beijing Tiantan Hospital
2026-01-30 – 2026-08 · Fibromyalgia, Pregabalin, Pain
What this study did
NCT05704374 · Istanbul Physical Medicine Rehabilitation Training and Research Hospital
2023-11-02 – 2023-12-01 · Fibromyalgia
What this study did
NCT04316702 · Assaf-Harofeh Medical Center
2020-03-01 – 2023-11-30 · Fibromyalgia, Emotional Trauma
What this study did
NCT03325959 · Assaf-Harofeh Medical Center
2017-03-01 – 2022-06-01 · Fibromyalgia, Hyperbaric Oxygen
What this study did
NCT03905486 · Yousra Hisham Abdel Fattah
2019-04-01 – 2019-12-31 · Fibromyalgia, Primary
What this study did
NCT01268631 · Tel-Aviv Sourasky Medical Center
2011-01 – 2013-01 · Fibromyalgia
What this study did
Other / comorbidity
NCT07549490 · National Center for Complementary and Integrative Health (NCCIH)
2026-11-24 – 2030-12-31 · Acute Pain
What this study did
NCT07635394 · Beijing Tiantan Hospital
2026-04-07 – 2029-03-31 · Irritable Bowel Syndrome (IBS)
What this study did
NCT07935252 · Beijing Tiantan Hospital
2026-11-10 – 2028-04-01 · Acute and Chronic Postsurgical Pain
What this study did
NCT07880223 · Moumtzidou Maria Aikaterini
2026-10-19 – 2027-11 · Postoperative Pain, Pain Management, Breast Surgery, Chronic Postoperative Pain
What this study did
NCT07344467 · Tanta University
2026-01-17 – 2027-06-01 · Oral, Melatonin, Pregabalin, Postoperative Pain, Anxiety, Spine Surgery
What this study did
NCT07630753 · Benha University
2026-05-25 – 2027-01-10 · Pregabalin, Optic Nerve Sheath Diameter Measurement, Intracranial Pressure Changes
What this study did
NCT07421427 · Cairo University
2026-02-21 – 2027-01-01 · Amantadine, Duloxetine, Pregabalin, Mastectomy, Pain Syndrome
What this study did
NCT06155916 · Helsinki University Central Hospital
2022-11-22 – 2026-12 · Neuropathic Pain, Insomnia, Sleep Disorder
What this study did
NCT07456761 · South Egypt Cancer Institute
2026-04 – 2026-12 · Laparoscopic Abdominal Surgeries
What this study did
NCT07606638 · Mayo Hospital Lahore
2026-02-01 – 2026-07-30 · Oral Cancer, Oral Cavity Cancer, Oral Squamous Cell Carcinoma (OSCC)
What this study did
NCT07598474 · University of Faisalabad
2026-01-01 – 2026-07-19 · Knee Osteoarthritis
What this study did
NCT07613476 · University of Faisalabad
2026-01-01 – 2026-07-19 · Carpal Tunnel Syndrome (CTS)
What this study did
NCT06896994 · Beijing Tiantan Hospital
2025-04-01 – 2026-05-01 · Postherpetic Neuralgia
What this study did
NCT06066918 · Loewenstein Hospital
2021-07-13 – 2026-02-05 · Spinal Cord Injuries, Spinal Cord Diseases
What this study did
NCT06420778 · Zhejiang Chinese Medical University
2024-07-12 – 2025-12-31 · Postherpetic Neuralgia, Electroacupuncture, Infrared Thermography
What this study did
NCT07389551 · Muhammad Aamir Latif
2025-07-01 – 2025-12-31 · Orthopedic Surgery
What this study did
NCT07000201 · Cairo University
2025-09-15 – 2025-12-30 · Anxiety, Anxiety Disorder (Panic Disorder or GAD)
What this study did
NCT06833203 · Cairo University
2023-12-01 – 2025-05-01 · Amantadine, Pregabalin, Post-thoracotomy Pain Syndrome
What this study did
NCT05935059 · National Cancer Institute, Egypt
2023-06-21 – 2025-03-01 · Post-mastectomy Pain Syndrome
What this study did
NCT06357260 · Postgraduate Institute of Dental Sciences Rohtak
2024-04-01 – 2025-03 · Trigeminal Neuralgia
What this study did
NCT05795478 · Beijing Tiantan Hospital
2023-10-24 – 2024-12-31 · Chronic Post Operative Pain, Oxycodone, Pregabalin, Postoperative Complications
What this study did
NCT05248152 · University Medical Centre Ljubljana
2022-01-13 – 2024-04-13 · Postoperative Pain
What this study did
NCT04662125 · Zagazig University
2020-12-10 – 2023-08-30 · Analgesia
What this study did
NCT04471233 · Northwell Health
2020-12-09 – 2023-06-20 · Knee Osteoarthritis, Pain, Postoperative
What this study did
NCT05254652 · The Catholic University of Korea
2022-05 – 2023-05 · Osteoarthritis
What this study did
NCT05322681 · The Catholic University of Korea
2022-05 – 2023-05 · Osteoarthritis
What this study did
NCT05455944 · Sameh Fathy
2020-01-01 – 2021-12-30 · Dacryocystitis
What this study did
NCT04708353 · Zagazig University
2020-08-20 – 2021-11 · Gynecologic Disease
What this study did
NCT03926000 · Menoufia University
2019-06 – 2019-12 · Knee Arthroscopy
What this study did
NCT03942796 · Mansoura University
2018-01-01 – 2019-10-30 · Chronic Post-thoracotomy Pain
What this study did
NCT03691038 · Kangbuk Samsung Hospital
2018-10-10 – 2019-10-30 · Pain, Neuropathic
What this study did
NCT03301025 · Mansoura University
2018-01-08 – 2019-04-30 · Spine Surgery
What this study did
NCT03211728 · Yonsei University
2017-07-19 – 2019-02-08 · Anterior Cruciate Ligament (ACL) Reconstruction
What this study did
NCT03530280 · Ankara Diskapi Training and Research Hospital
2018-06-01 – 2018-12-01 · Postoperative Pain After Knee Arthroscopy
What this study did
NCT03721432 · Beni-Suef University
2018-05-20 – 2018-11-15 · Epidural Anesthesia, Shivering
What this study did
NCT04259073 · Hôpital Universitaire Fattouma Bourguiba
2018-03-01 – 2018-10-10 · Postoperative Pain
What this study did
NCT02394951 · Washington University School of Medicine
2015-04 – 2018-04-02 · Neuropathy, Pain
What this study did
Used as active comparator (61)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Diabetic Peripheral Neuropathic Pain
NCT06715462 · Eurofarma Laboratorios S.A.
2026-04 – 2028-03 · Painful Diabetic Peripheral Neuropathy (PDPN)
What this study did
NCT06628908 · Vertex Pharmaceuticals Incorporated
2024-10-01 – 2027-05-31 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT01863810 · KunWha Pharmaceutical Co., Ltd.
2013-08 – 2014-10 · Diabetic Neuropathy
What this study did
Fibromyalgia
NCT02146430 · Daiichi Sankyo
2014-10-27 – 2016-07-14 · Pain Associated With Fibromyalgia
What this study did
NCT02187159 · Daiichi Sankyo
2014-11 – 2016-07-07 · Pain Associated With Fibromyalgia
What this study did
Other / comorbidity
NCT04666714 · EMS
2023-05-15 – 2025-12-31 · Neuropathic Pain
What this study did
NCT03794388 · Institut Cancerologie de l'Ouest
2019-03-19 – 2022-11-18 · Breast Cancer Patient
What this study did
NCT03221907 · Daewon Pharmaceutical Co., Ltd.
2016-04-11 – 2019-01-08 · Pain of Mononeuropathy
What this study did
NCT03186443 · Second Affiliated Hospital of Guangzhou Medical University
2017-10-01 – 2017-10-01 · Herpetic Neuralgia
What this study did
Phase 2/3 (1)
Diabetic Peripheral Neuropathic Pain
NCT04647773 · Haisco Pharmaceutical Group Co., Ltd.
2020-12-02 – 2022-11-16 · Diabetic Peripheral Neuropathic Pain
What this study did
Phase 2 (21)
Diabetic Peripheral Neuropathic Pain
NCT06619860 · Vertex Pharmaceuticals Incorporated
2024-10-18 – 2027-04-22 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT06221241 · Jemincare
2024-03-25 – 2025-04-30 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT05660538 · Vertex Pharmaceuticals Incorporated
2022-12-20 – 2023-10-25 · Diabetic Peripheral Neuropathy
What this study did
NCT04641273 · Bayer
2021-01-22 – 2021-10-18 · Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
What this study did
NCT02673866 · Daiichi Sankyo
2016-02 – 2017-02 · Neuropathic Pain, Diabetes
What this study did
NCT02372578 · Astellas Pharma Global Development, Inc.
2015-05-27 – 2016-05-20 · Painful Diabetic Peripheral Neuropathy (PDPN)
What this study did
NCT01928381 · AstraZeneca
2013-11 – 2015-05 · Diabetic Neuropathy, Painful; Diabetic Neuropathies
What this study did
NCT01939366 · Tris Pharma, Inc.
2013-09-27 – 2015-01-28 · Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
What this study did
NCT01504412 · Daiichi Sankyo Co., Ltd.
2012-01 – 2013-06 · Pain, Diabetic Peripheral Neuropathy
What this study did
NCT01496365 · Daiichi Sankyo
2011-11-28 – 2012-09-07 · Diabetic Peripheral Neuropathy
What this study did
NCT01345045 · AbbVie (prior sponsor, Abbott)
2011-04 – 2011-10 · Diabetic Neuropathic Pain
What this study did
NCT00870454 · SK Life Science, Inc.
2009-05 – 2010-12 · Diabetic Neuropathies
What this study did
NCT00785577 · Eli Lilly and Company
2008-11 – 2010-06 · Diabetic Neuropathy, Painful
What this study did
NCT00838799 · Forest Laboratories
2009-02 – 2010-04 · Diabetic Peripheral Neuropathic Pain
What this study did
Fibromyalgia
NCT00696787 · Wyeth is now a wholly owned subsidiary of Pfizer
2008-06 – 2009-01 · Fibromyalgia
What this study did
Other / comorbidity
NCT07758920 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
2026-08 – 2027-06 · Postherpetic Neuralgia ( PHN )
What this study did
NCT06766916 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-05-07 – 2026-12-31 · Neuropathic Pain
What this study did
NCT05763550 · Haisco Pharmaceutical Group Co., Ltd.
2023-02-27 – 2023-08-07 · Herpetic Neuralgia
What this study did
NCT01688947 · Purdue Pharma LP
2012-09 – 2014-04 · Postherpetic Neuralgia, Pain
What this study did
NCT01485094 · Grünenthal GmbH
2012-02 – 2013-01 · Neuralgia
What this study did
NCT01058642 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2010-01 – 2010-12 · Postherpetic Neuralgia
What this study did
Phase 1 (8)
Diabetic Peripheral Neuropathic Pain
NCT07377721 · Shandong Suncadia Medicine Co., Ltd.
2026-03-24 – 2026-11 · Diabetic Peripheral Neuropathic Pain
What this study did
Other / comorbidity
NCT05181852 · Initiator Pharma
2022-01-05 – 2022-07-01 · Pain
What this study did
NCT03261427 · Yungjin Pharm. Co., Ltd.
2017-09-14 – 2018-03-29 · Healthy
What this study did
NCT04499209 · Xgene Pharmaceutical Group
2017-10-16 – 2018-03-19 · Pain
What this study did
NCT02260947 · Pfizer
2014-10 – 2014-12 · Healthy
What this study did
NCT02238717 · Pfizer
2014-09 – 2014-11 · Healthy
What this study did
NCT02103647 · IlDong Pharmaceutical Co Ltd
2013-05 – 2013-06 · Healthy
What this study did
Phase 4 (11)
Diabetic Peripheral Neuropathic Pain
NCT07451431 · Bangladesh Medical University
2025-10-01 – 2027-05 · Diabetic Peripheral Neuropathic Pain (DPNP)
What this study did
NCT02417935 · Eli Lilly and Company
2015-04 – 2017-05-13 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT01364298 · Merck KGaA, Darmstadt, Germany
2011-04 – 2012-07 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT00385671 · Eli Lilly and Company
2006-09 – 2009-11 · Diabetic Neuropathy, Painful
What this study did
Fibromyalgia
NCT07708948 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2024-01-01 – 2026-03-01 · Fibromyalgia Syndrome
What this study did
Other / comorbidity
NCT03348735 · University Hospital, Antwerp
2018-12-03 – 2021-04-19 · Neuropathic Pain
What this study did
NCT03604354 · All India Institute of Medical Sciences, Bhubaneswar
2018-08-01 – 2020-05-19 · Osteoarthritis, Knee
What this study did
NCT03512574 · Wonkwang University Hospital
2018-01-02 – 2018-03-30 · Pain, Postoperative
What this study did
NCT01888536 · Yungjin Pharm. Co., Ltd.
2013-02 – 2014-02 · Neurologic Claudication in Patients With Lumbar Spinal Stenosis
What this study did
NCT01713426 · Astellas Pharma Europe Ltd.
2012-07-11 – 2013-09-26 · Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)
What this study did
NCT01352741 · Grünenthal GmbH
2011-03 – 2012-01 · Low Back Pain, Neuropathic Pain
What this study did
Early phase / not applicable (11)
Fibromyalgia
NCT07196657 · Beijing Tiantan Hospital
2025-09-30 – 2027-08-31 · Fibromyalgia, Pregabalin, Pain
What this study did
NCT07157852 · Beijing Tiantan Hospital
2025-09-05 – 2027-08-31 · Fibromyalgia, Pregabalin, Mirogabalin, Pain
What this study did
NCT03890133 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019-04-01 – 2022-12-31 · Fibromyalgia
What this study did
NCT03797560 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019-03-22 – 2022-10-31 · Fibromyalgia
What this study did
Other / comorbidity
NCT06328062 · Thammasat University Hospital
2024-04-01 – 2026-08-31 · Pain Postoperative, Osteoarthritis, Total Knee Arthroplasty
What this study did
NCT06301061 · Federico II University
2024-04-01 – 2026-04-01 · Pain, Chronic, Lumbosacral Radiculopathy, Radicular; Neuropathic
What this study did
NCT06261801 · The Third People's Hospital of Hangzhou
2024-02-07 – 2025-12-20 · Trigeminal Herpetic Neuralgia
What this study did
NCT06969417 · CMH Kharian Medical College
2025-04-10 – 2025-09-30 · Herpes Zoster (HZ), Post Herpetic Neuralgia (PHN)
What this study did
NCT07587645 · ISSSTE Hospital Regional "Gral. Ignacio Zaragoza"
2024-06-19 – 2024-07-05 · Acute Postoperative Pain, Lower Limb Surgery
What this study did
NCT04847245 · Peking University
2021-05-01 – 2023-03-01 · Chronic Visceral Pain, Major Depressive Disorder
What this study did
NCT01168531 · Yonsei University
2009-12 – 2011-03 · Pain
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Epilepsy
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
Early phase / not applicable (6)
Other / comorbidity
NCT07593313 · Nanchong Central Hospital
2024-01-01 – 2029-08-01 · Central Post-Stroke Pain
What this study did
NCT07515885 · Dexiong Han
2025-09-01 – 2028-12-31 · Acute Herpes Zoster
What this study did
NCT07818577 · Beijing Tiantan Hospital
2026-10-01 – 2027-12-01 · Chronic Pelvic Pain, Chronic Pelvic Pain Syndrome
What this study did
NCT06990854 · Dexiong Han
2025-07-01 – 2026-12 · Postherpetic Neuralgia ( PHN )
What this study did
NCT03494426 · Assiut University
2018-04-01 – 2020-01-01 · Post-Mastectomy Chronic Pain Syndrome
What this study did
NCT02600247 · The Catholic University of Korea
2015-11 – 2016-11 · Osteoarthritis
What this study did

Competitive landscape

Other α2δ subunit of voltage-gated calcium channels drugs

Gabapentin. Compare all 2 α2δ subunit of voltage-gated calcium channels drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pregabalin: this drugApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 12 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pregabalin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Early phase / not applicableLaparoscopic Abdominal SurgeriesNot yet recruiting
Est. primary completion 2026-11 · NCT07456761 · CT.gov ↗
What to watch
December 2026 (2)
Phase 1Post Operative Pain, AcuteRecruiting
Est. primary completion 2026-12 · NCT05150795 · CT.gov ↗
What to watch
Early phase / not applicablePregabalin, Optic Nerve Sheath Diameter Measurement, Intracranial Pressure ChangesActive not recruiting
Est. primary completion 2026-12-10 · NCT07630753 · CT.gov ↗
What to watch
2027 (13)
January 2027 (1)
Early phase / not applicableAmantadine, Duloxetine, Pregabalin, Mastectomy, Pain SyndromeRecruiting
Est. primary completion 2027-01-01 · NCT07421427 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain SensitivityRecruiting
Est. primary completion 2027-03-30 · NCT07400471 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Early-stage Breast Cancer, Estrogen-receptor-positive Breast CancerRecruiting
Est. primary completion 2027-04-20 · NCT06150898 · CT.gov ↗
What to watch
June 2027 (7)
Phase 3Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2027-06-01 · NCT07712913 · CT.gov ↗
What to watch
Early phase / not applicableOral, Melatonin, Pregabalin, Postoperative Pain, Anxiety, Spine SurgeryRecruiting
Est. primary completion 2027-06-01 · NCT07344467 · CT.gov ↗
What to watch
Phase 2Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)Recruiting
Est. primary completion 2027-06-30 · NCT07913074 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaRecruiting
Est. primary completion 2027-06-30 · NCT07171320 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaRecruiting
Est. primary completion 2027-06-30 · NCT07208357 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaRecruiting
Est. primary completion 2027-06-30 · NCT07230197 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaRecruiting
Est. primary completion 2027-06-30 · NCT07186751 · CT.gov ↗
What to watch
August 2027 (1)
Early phase / not applicablePostoperative Pain, Pain Management, Breast Surgery, Chronic Postoperative PainRecruiting
Est. primary completion 2027-08 · NCT07880223 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Bladder Pain Syndrome, Pregabalin, Educational Behavioral Intervention, Urinary UrgencyNot yet recruiting
Est. primary completion 2027-10-31 · NCT07752134 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableAcute and Chronic Postsurgical PainNot yet recruiting
Est. primary completion 2027-12-30 · NCT07935252 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 2Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2028-06-01 · NCT06614322 · CT.gov ↗
What to watch
2029 (2)
September 2029 (1)
Phase 4Cough, Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity Syndrome, Chronic CoughNot yet recruiting
Est. primary completion 2029-09-01 · NCT07288528 · CT.gov ↗
What to watch
December 2029 (1)
Early phase / not applicableAcute PainNot yet recruiting
Est. primary completion 2029-12-31 · NCT07549490 · CT.gov ↗
What to watch

See the full readout calendar ↗